Ergoteles’s Clearside Biomedical CLSD Stock Holding History

Ergoteles’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,657	Closed	-$61.4K	–	1330
2022 Q4	$61.4K	Buy	+3,657	New	+$65.9K	﹤0.01%	1276

Other funds holding CLSD

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Ergoteles's CLSD Position: Q1 2023 in Review

Ergoteles sold out of Clearside Biomedical (CLSD) in Q1 2023, closing a stake of 3,657 shares — an estimated $61.4K sold.

Ergoteles first reported a position in CLSD in Q4 2022 and held it in 1 quarter. The position peaked at $61.4K in Q4 2022. 50 funds tracked by Wall St. Rank hold CLSD as of Q1 2023.

Ergoteles reported no remaining Clearside Biomedical position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 3,657 Clearside Biomedical shares in Q1 2023, an estimated $61.4K.
Ergoteles first reported a position in Clearside Biomedical in Q4 2022 and held it in 1 quarter.
Ergoteles's Clearside Biomedical position peaked at $61.4K in Q4 2022.
50 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.